Clinical trials
Phase 2 trials in Moldova
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
102 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 6 |
| 2014 | 2 |
| 2015 | 11 |
| 2016 | 9 |
| 2017 | 7 |
| 2018 | 3 |
| 2019 | 6 |
| 2020 | 7 |
| 2021 | 8 |
| 2022 | 9 |
| 2023 | 5 |
| 2024 | 7 |
| 2025 | 8 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 55 |
| Terminated | 16 |
| Active, not recruiting | 14 |
| Recruiting | 9 |
| Unknown status | 5 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 6 |
| Lakefront Biotherapeutics NV | 6 |
| Pfizer | 4 |
| UCB Biopharma SRL | 4 |
| Ablynx, a Sanofi company | 3 |
| Atea Pharmaceuticals, Inc. | 3 |
| Gilead Sciences | 3 |
| Regeneron Pharmaceuticals | 3 |
| Spyre Therapeutics, Inc. | 3 |
| SynAct Pharma Aps | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Arthritis, Rheumatoid | 19 |
| Colitis, Ulcerative | 14 |
| Inflammatory Bowel Diseases | 8 |
| Hepatitis B, Chronic | 6 |
| Major Depressive Disorder | 5 |
| Crohn Disease | 4 |
| Hepatitis | 4 |
| Hepatitis B | 4 |
| Hepatitis C, Chronic | 4 |
| Hepatitis D | 4 |
Trials
Showing 26 to 50 of 102. Each trial links to its page on Pharma Observatory.
2 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.